Company intelligence / Profile preview
Biomed Industries
San Jose, California, United Statesbiomedind.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NA‑831 has shown significant efficacy and safety in a Phase 2 clinical trial for Alzheimer’s disease with improvement in cognitive scores and no major adverse events. The company is advancing to Phase 3 trials. Other candidates have demonstrated promising safety profiles and early efficacy signals for MDD, Rett Syndrome, ALS/Parkinson's Disease, and obesity/metabolic disorders[4][5].
- Therapeutic areas
- PsychiatryNeurologyMetabolic Disorders
- Modalities
- Small moleculeDevice (for MICROS infusion system)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Biomed Industries.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomed Industries.